Pharmidex at Advanced Therapies Integrates 2024!
December 2, 2024
Ash Alavijeh and
Janette Dalay Robertson, were thrilled to attend the dynamic and insightful conference. The sessions were packed with thought-provoking discussions.
Special thanks to the organisers at Life Science Integrates,
Cell and Gene Therapy Catapult and
GSK for creating such a fantastic space to connect and share ideas.
Oh, and a fun side note:
Janette Dalay Robertson might have spent a bit too much time experimenting with the Virtual Reality glasses! ๐ถ๏ธ Let’s just say She's ready for the metaverse now. ๐
Looking forward to continuing the conversations we started and exploring potential collaborations with some of the amazing people we met!
#AdvancedTherapiesIntegrates #Networking #Innovation #Pharmidex #catapultcellandgenetherapy #GSK
A big thank you to our interns from City St George’s, University of London and heir fantastic contribution to Pharmidex over the past few months. They have supported scientific projects across the business, developed valuable technical skills and gained hands-on experience within a CRO environment. Their contribution has extended beyond the laboratory, helping with our website, marketing materials, conference preparation and business development activities. Science drives success, but communicating that science effectively is just as important. Our interns have helped us do both. Thank you for your hard work, enthusiasm, and dedication. We wish you every success in the next stage of your careers.
On 18 June, our COO, Ash Alavijeh , will join an industry panel discussing: "What are the advantages and disadvantages of working with UK-based Discovery CROs?" The session will explore the value of UK CROs in supporting innovation, protecting IP, accessing scientific expertise and accelerating drug discovery programmes. ๐
18 June 2025 ๐ Cambridge ๐ Panel Session: 12:20–12:45 We look forward to connecting with colleagues, collaborators, and innovators from across the life sciences community.
This well-deserved appointment marks an important milestone in a remarkable career spanning more than 22 years at Pharmidex . Over the years, Dr Chishty has made a significant contribution to the growth of our DMPK capabilities, applying his extensive expertise in Drug Metabolism and Pharmacokinetics to support successful drug discovery and development programmes for clients worldwide. His scientific leadership, dedication and commitment to excellence have been instrumental in strengthening our services and supporting the continued success of Pharmidex . As we continue to grow and support innovative biopharmaceutical companies, we look forward to the impact Dr Chishty will make in this new role. Please join us in congratulating Dr Mansoor Chishty on this achievement and wishing him every success as Director of DMPK.
